You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,861,833


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,861,833
Title:Methods of treating melanoma
Abstract: The present disclosure is directed to methods of treating malignant melanoma by irradiating sites to which melanoma cells have become locally advanced, surgically undesirable, or have metastasized. In various embodiments of the invention, patients are treated with radiation doses in amounts ranging from about 25 to 230 cGy, preferably about 100 cGy to about 200 cGy, at least twice a day. The treatment regimen can be performed in the absence of additional treatments for the metastatic melanoma (e.g., chemotherapy/targeted therapy/immunotherapy) or in combination with additional therapies for chemotherapy/targeted therapy/immunotherapy. Various additional embodiments relate to the administration of between 20 and 100 fractions of radiation, preferably between 20 and 56 fractions of radiation.
Inventor(s): Anderson; Norman H. (Ocala, FL)
Assignee:
Application Number:15/473,902
Patent Claims:1. A method for treating malignant melanoma in a subject comprising irradiating malignant melanoma within the subject with at least two fractions of radiation per day, said fractions of radiation being between about 100 to about 160 centiGray (cGy) and said fractions being separated by a time interval of at least about 0.5 hour.

2. The method according to claim 1, wherein the fractions of radiation are separated by a time interval ranging from about 1 hour and, maximally, about 23 hours.

3. The method according to claim 1, wherein the fractions of radiation are separated by a time interval ranging from about 1 hour and about 8 hours.

4. The method according to claim 1, wherein the fractions of radiation are separated by a time interval ranging from about 2 hours and about 8 hours.

5. The method according to claim 1, wherein the fractions of radiation are separated by a time interval ranging from about 1 hour and about 6 hours.

6. The method according to claim 1, said method comprising treating said subject with radiation and a therapy comprising surgery, chemotherapy, targeted immunotherapy, immunotherapy or a combination of said therapies.

7. The method according to claim 6, wherein said chemotherapy, targeted immunotherapy or immunotherapy is selected from treatment with vemurafenib, dabrafenib, trametinib, cobimetinib, temozolomide, dacarbazine, paclitaxel or combinations thereof.

8. The method according to claim 7, wherein said subject is treated with a total of between 20 and 100 fractions of radiation.

9. The method according to claim 8, wherein said subject is treated with a total of between 20 and 56 fractions of radiation.

10. The method according to claim 6, wherein said chemotherapy, targeted immunotherapy or immunotherapy is selected from treatment with pembrolizumab, ipilmumab, nivolumab, interferon alpha, interferon alpha 2b or combinations thereof.

11. The method according to claim 10, wherein said subject is treated with a total of between 20 and 100 fractions of radiation.

12. The method according to claim 11, wherein said subject is treated with a total of between 20 and 56 fractions of radiation.

13. The method according to claim 6, wherein said subject is treated with a total of between 20 and 100 fractions of radiation.

14. The method according to claim 13, wherein said subject is treated with a total of between 20 and 56 fractions of radiation.

15. The method according to claim 1, wherein said subject is treated with a total of between 20 and 100 fractions of radiation.

16. The method according to claim 15, wherein said subject is treated with a total of between 20 and 56 fractions of radiation.

17. The method according to claim 1, said method comprising irradiating malignant melanoma within the subject with at least two fractions of radiation per day, said fractions of radiation being between about 100 to about 135 centiGray (cGy) and said fractions being separated by a time interval of at least about 0.5 hour.

Details for Patent 9,861,833

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab For Injection 125514 09/04/2014 ⤷  Try a Trial 2039-02-26
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab Injection 125514 01/15/2015 ⤷  Try a Trial 2039-02-26
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 12/22/2014 ⤷  Try a Trial 2039-02-26
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 10/04/2017 ⤷  Try a Trial 2039-02-26
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 08/27/2021 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.